Global Immuno-oncology Drugs Market

Immuno-oncology Drugs Comprehensive Study by Type (Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cytokine-Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy), Application (Hospitals, Pharmacies, Online Pharmacies), Therapies (Iplimumab, Nivolumab, Rituximab, Blinatumomab, Aldesleukin, Recombinant human papillomavirus vaccine (Gardasil), Tisagenlecleucel (Kymriah)), Sales Channel (Direct, Indirect) Players and Region - Global Market Outlook to 2030

Immuno-oncology Drugs Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 20.3%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
According to the International Agency for Research on Cancer around 18.1 million new cancer cases and 9.6 million cancer deaths. Immuno-oncology refers to the use of the body's natural defenses to treat cancer and works by stimulating the immune system instead of fighting the tumors, avoiding disturbance in the functionality of healthy cells. It helps the immune system to recognize and target cancer cells. Further, ongoing clinical trials for the development of innovative products for cancer treatment is driving the Global Immuno-Oncology market. According to AMA Research, the market for Immuno-oncology Drugs is expected to register a CAGR of 20.3% during the forecast period to 2030. This growth is primarily driven by Introduction of Novel Oncology Therapies with Lesser Side Effects .

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Volume UnitN
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Health Care Supplies sector in the North America region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Amgen, Inc (United States), AstraZeneca, Plc (United Kingdom), Bristol-Myers Squibb (United States), Celgene Corporation (United States), Eli Lilly and Company (United States), Merck & Co.(United States), Hoffmann-La Roche AG (Switzerland), Johnson & Johnson (United States), Novartis International AG (Switzerland), AbbVie, Inc. (United States), Pfizer Inc. (United States), Sanofi S.A. (France), EMD Serono, Inc. (United States), Gilead Sciences Inc. (United States), Prometheus Therapeutics & Diagnostics (United States), Aduro BioTech (United States) and Galena Biopharma (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
In 2017, Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy and rare-cell detection products, and IncellDx, a single-cell diagnostic company offering transformative diagnostic and prognostic clinical patient information based on a reagent platform allowing simultaneous, quantitative single cell-analysis of proteomic and genomic biomarkers, announced that they have entered into a collaboration to determine the feasibility of using peripheral blood to perform IncellDx’s Quantitative PD-L1 assay (OncoTect iO™) on Celsee’s rare cell isolation and analysis platforms, that may predict therapy response to metastatic cancers
In February 2018, Opdivo-Yervoy combination therapy showed delayed disease progression in patients with advanced non-small cell lung cancer.The Global Immuno Oncology Drugs Market is fragmented with numerous market players. The key players in the market are focused on launching new products in the market, which is also expected to be another factor to drive market growth. Further, increasing incidence rate of cancer with various research and development activities, owing to benefits related to cancer treatment is propelling the market growth

Influencing Trend:
Ongoing Clinical Trial for the Development of Innovative Products and Emergence of Targeted and Combination Therapies

Market Growth Drivers:
Introduction of Novel Oncology Therapies with Lesser Side Effects, Improved Therapeutic Outcomes in Cancer Treatment, Rising Prevalence of Cancer and Usage of Number of Therapies, Growing Geriatric Population and High Healthcare Spending in Developed Economies

Challenges:
Lack of Awareness about the Therapeutic Drug Treatment and Increasing Number of Side Effects Post Immuno Oncology Therapy

Restraints:
High Cost of Immuno-Oncology Therapies

Opportunities:
Companies Offering Opportunities for Next Generation Immunotherapy

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Immuno-oncology Drugs Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Immuno-oncology Drugs Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Immuno-oncology Drugs players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Immuno-oncology Drugs Study Sheds Light on
— The Immuno-oncology Drugs Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Immuno-oncology Drugs industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Immuno-oncology Drugs industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Immune Checkpoint Inhibitors
  • Monoclonal Antibodies
  • Cytokine-Based Immunotherapy
  • Cancer Vaccines
  • CAR-T Cell Therapy
By Application
  • Hospitals
  • Pharmacies
  • Online Pharmacies
By Therapies
  • Iplimumab
  • Nivolumab
  • Rituximab
  • Blinatumomab
  • Aldesleukin
  • Recombinant human papillomavirus vaccine (Gardasil)
  • Tisagenlecleucel (Kymriah)

By Sales Channel
  • Direct
  • Indirect

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Introduction of Novel Oncology Therapies with Lesser Side Effects
      • 3.2.2. Improved Therapeutic Outcomes in Cancer Treatment
      • 3.2.3. Rising Prevalence of Cancer and Usage of Number of Therapies
      • 3.2.4. Growing Geriatric Population
      • 3.2.5. High Healthcare Spending in Developed Economies
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness about the Therapeutic Drug Treatment
      • 3.3.2. Increasing Number of Side Effects Post Immuno Oncology Therapy
    • 3.4. Market Trends
      • 3.4.1. Ongoing Clinical Trial for the Development of Innovative Products
      • 3.4.2. Emergence of Targeted and Combination Therapies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Immuno-oncology Drugs, by Type, Application, Therapies, Sales Channel and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Immuno-oncology Drugs (Value)
      • 5.2.1. Global Immuno-oncology Drugs by: Type (Value)
        • 5.2.1.1. Immune Checkpoint Inhibitors
        • 5.2.1.2. Monoclonal Antibodies
        • 5.2.1.3. Cytokine-Based Immunotherapy
        • 5.2.1.4. Cancer Vaccines
        • 5.2.1.5. CAR-T Cell Therapy
      • 5.2.2. Global Immuno-oncology Drugs by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Pharmacies
        • 5.2.2.3. Online Pharmacies
      • 5.2.3. Global Immuno-oncology Drugs by: Therapies (Value)
        • 5.2.3.1. Iplimumab
        • 5.2.3.2. Nivolumab
        • 5.2.3.3. Rituximab
        • 5.2.3.4. Blinatumomab
        • 5.2.3.5. Aldesleukin
        • 5.2.3.6. Recombinant human papillomavirus vaccine (Gardasil)
        • 5.2.3.7. Tisagenlecleucel (Kymriah)
      • 5.2.4. Global Immuno-oncology Drugs by: Sales Channel (Value)
        • 5.2.4.1. Direct
        • 5.2.4.2. Indirect
      • 5.2.5. Global Immuno-oncology Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Immuno-oncology Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Amgen, Inc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AstraZeneca, Plc (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bristol-Myers Squibb (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Celgene Corporation (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Eli Lilly and Company (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck & Co.(United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Hoffmann-La Roche AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Johnson & Johnson (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis International AG (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AbbVie, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Pfizer Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Sanofi S.A. (France)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. EMD Serono, Inc. (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Gilead Sciences Inc. (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Prometheus Therapeutics & Diagnostics (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. Aduro BioTech (United States)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
      • 6.4.17. Galena Biopharma (United States)
        • 6.4.17.1. Business Overview
        • 6.4.17.2. Products/Services Offerings
        • 6.4.17.3. Financial Analysis
        • 6.4.17.4. SWOT Analysis
  • 7. Global Immuno-oncology Drugs Sale, by Type, Application, Therapies, Sales Channel and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Immuno-oncology Drugs (Value)
      • 7.2.1. Global Immuno-oncology Drugs by: Type (Value)
        • 7.2.1.1. Immune Checkpoint Inhibitors
        • 7.2.1.2. Monoclonal Antibodies
        • 7.2.1.3. Cytokine-Based Immunotherapy
        • 7.2.1.4. Cancer Vaccines
        • 7.2.1.5. CAR-T Cell Therapy
      • 7.2.2. Global Immuno-oncology Drugs by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Pharmacies
        • 7.2.2.3. Online Pharmacies
      • 7.2.3. Global Immuno-oncology Drugs by: Therapies (Value)
        • 7.2.3.1. Iplimumab
        • 7.2.3.2. Nivolumab
        • 7.2.3.3. Rituximab
        • 7.2.3.4. Blinatumomab
        • 7.2.3.5. Aldesleukin
        • 7.2.3.6. Recombinant human papillomavirus vaccine (Gardasil)
        • 7.2.3.7. Tisagenlecleucel (Kymriah)
      • 7.2.4. Global Immuno-oncology Drugs by: Sales Channel (Value)
        • 7.2.4.1. Direct
        • 7.2.4.2. Indirect
      • 7.2.5. Global Immuno-oncology Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Immuno-oncology Drugs: by Type(USD Million)
  • Table 2. Immuno-oncology Drugs Immune Checkpoint Inhibitors , by Region USD Million (2018-2023)
  • Table 3. Immuno-oncology Drugs Monoclonal Antibodies , by Region USD Million (2018-2023)
  • Table 4. Immuno-oncology Drugs Cytokine-Based Immunotherapy , by Region USD Million (2018-2023)
  • Table 5. Immuno-oncology Drugs Cancer Vaccines , by Region USD Million (2018-2023)
  • Table 6. Immuno-oncology Drugs CAR-T Cell Therapy , by Region USD Million (2018-2023)
  • Table 7. Immuno-oncology Drugs: by Application(USD Million)
  • Table 8. Immuno-oncology Drugs Hospitals , by Region USD Million (2018-2023)
  • Table 9. Immuno-oncology Drugs Pharmacies , by Region USD Million (2018-2023)
  • Table 10. Immuno-oncology Drugs Online Pharmacies , by Region USD Million (2018-2023)
  • Table 11. Immuno-oncology Drugs: by Therapies(USD Million)
  • Table 12. Immuno-oncology Drugs Iplimumab , by Region USD Million (2018-2023)
  • Table 13. Immuno-oncology Drugs Nivolumab , by Region USD Million (2018-2023)
  • Table 14. Immuno-oncology Drugs Rituximab , by Region USD Million (2018-2023)
  • Table 15. Immuno-oncology Drugs Blinatumomab , by Region USD Million (2018-2023)
  • Table 16. Immuno-oncology Drugs Aldesleukin , by Region USD Million (2018-2023)
  • Table 17. Immuno-oncology Drugs Recombinant human papillomavirus vaccine (Gardasil) , by Region USD Million (2018-2023)
  • Table 18. Immuno-oncology Drugs Tisagenlecleucel (Kymriah) , by Region USD Million (2018-2023)
  • Table 19. Immuno-oncology Drugs: by Sales Channel(USD Million)
  • Table 20. Immuno-oncology Drugs Direct , by Region USD Million (2018-2023)
  • Table 21. Immuno-oncology Drugs Indirect , by Region USD Million (2018-2023)
  • Table 22. South America Immuno-oncology Drugs, by Country USD Million (2018-2023)
  • Table 23. South America Immuno-oncology Drugs, by Type USD Million (2018-2023)
  • Table 24. South America Immuno-oncology Drugs, by Application USD Million (2018-2023)
  • Table 25. South America Immuno-oncology Drugs, by Therapies USD Million (2018-2023)
  • Table 26. South America Immuno-oncology Drugs, by Sales Channel USD Million (2018-2023)
  • Table 27. Brazil Immuno-oncology Drugs, by Type USD Million (2018-2023)
  • Table 28. Brazil Immuno-oncology Drugs, by Application USD Million (2018-2023)
  • Table 29. Brazil Immuno-oncology Drugs, by Therapies USD Million (2018-2023)
  • Table 30. Brazil Immuno-oncology Drugs, by Sales Channel USD Million (2018-2023)
  • Table 31. Argentina Immuno-oncology Drugs, by Type USD Million (2018-2023)
  • Table 32. Argentina Immuno-oncology Drugs, by Application USD Million (2018-2023)
  • Table 33. Argentina Immuno-oncology Drugs, by Therapies USD Million (2018-2023)
  • Table 34. Argentina Immuno-oncology Drugs, by Sales Channel USD Million (2018-2023)
  • Table 35. Rest of South America Immuno-oncology Drugs, by Type USD Million (2018-2023)
  • Table 36. Rest of South America Immuno-oncology Drugs, by Application USD Million (2018-2023)
  • Table 37. Rest of South America Immuno-oncology Drugs, by Therapies USD Million (2018-2023)
  • Table 38. Rest of South America Immuno-oncology Drugs, by Sales Channel USD Million (2018-2023)
  • Table 39. Asia Pacific Immuno-oncology Drugs, by Country USD Million (2018-2023)
  • Table 40. Asia Pacific Immuno-oncology Drugs, by Type USD Million (2018-2023)
  • Table 41. Asia Pacific Immuno-oncology Drugs, by Application USD Million (2018-2023)
  • Table 42. Asia Pacific Immuno-oncology Drugs, by Therapies USD Million (2018-2023)
  • Table 43. Asia Pacific Immuno-oncology Drugs, by Sales Channel USD Million (2018-2023)
  • Table 44. China Immuno-oncology Drugs, by Type USD Million (2018-2023)
  • Table 45. China Immuno-oncology Drugs, by Application USD Million (2018-2023)
  • Table 46. China Immuno-oncology Drugs, by Therapies USD Million (2018-2023)
  • Table 47. China Immuno-oncology Drugs, by Sales Channel USD Million (2018-2023)
  • Table 48. Japan Immuno-oncology Drugs, by Type USD Million (2018-2023)
  • Table 49. Japan Immuno-oncology Drugs, by Application USD Million (2018-2023)
  • Table 50. Japan Immuno-oncology Drugs, by Therapies USD Million (2018-2023)
  • Table 51. Japan Immuno-oncology Drugs, by Sales Channel USD Million (2018-2023)
  • Table 52. India Immuno-oncology Drugs, by Type USD Million (2018-2023)
  • Table 53. India Immuno-oncology Drugs, by Application USD Million (2018-2023)
  • Table 54. India Immuno-oncology Drugs, by Therapies USD Million (2018-2023)
  • Table 55. India Immuno-oncology Drugs, by Sales Channel USD Million (2018-2023)
  • Table 56. South Korea Immuno-oncology Drugs, by Type USD Million (2018-2023)
  • Table 57. South Korea Immuno-oncology Drugs, by Application USD Million (2018-2023)
  • Table 58. South Korea Immuno-oncology Drugs, by Therapies USD Million (2018-2023)
  • Table 59. South Korea Immuno-oncology Drugs, by Sales Channel USD Million (2018-2023)
  • Table 60. Taiwan Immuno-oncology Drugs, by Type USD Million (2018-2023)
  • Table 61. Taiwan Immuno-oncology Drugs, by Application USD Million (2018-2023)
  • Table 62. Taiwan Immuno-oncology Drugs, by Therapies USD Million (2018-2023)
  • Table 63. Taiwan Immuno-oncology Drugs, by Sales Channel USD Million (2018-2023)
  • Table 64. Australia Immuno-oncology Drugs, by Type USD Million (2018-2023)
  • Table 65. Australia Immuno-oncology Drugs, by Application USD Million (2018-2023)
  • Table 66. Australia Immuno-oncology Drugs, by Therapies USD Million (2018-2023)
  • Table 67. Australia Immuno-oncology Drugs, by Sales Channel USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Immuno-oncology Drugs, by Type USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Immuno-oncology Drugs, by Application USD Million (2018-2023)
  • Table 70. Rest of Asia-Pacific Immuno-oncology Drugs, by Therapies USD Million (2018-2023)
  • Table 71. Rest of Asia-Pacific Immuno-oncology Drugs, by Sales Channel USD Million (2018-2023)
  • Table 72. Europe Immuno-oncology Drugs, by Country USD Million (2018-2023)
  • Table 73. Europe Immuno-oncology Drugs, by Type USD Million (2018-2023)
  • Table 74. Europe Immuno-oncology Drugs, by Application USD Million (2018-2023)
  • Table 75. Europe Immuno-oncology Drugs, by Therapies USD Million (2018-2023)
  • Table 76. Europe Immuno-oncology Drugs, by Sales Channel USD Million (2018-2023)
  • Table 77. Germany Immuno-oncology Drugs, by Type USD Million (2018-2023)
  • Table 78. Germany Immuno-oncology Drugs, by Application USD Million (2018-2023)
  • Table 79. Germany Immuno-oncology Drugs, by Therapies USD Million (2018-2023)
  • Table 80. Germany Immuno-oncology Drugs, by Sales Channel USD Million (2018-2023)
  • Table 81. France Immuno-oncology Drugs, by Type USD Million (2018-2023)
  • Table 82. France Immuno-oncology Drugs, by Application USD Million (2018-2023)
  • Table 83. France Immuno-oncology Drugs, by Therapies USD Million (2018-2023)
  • Table 84. France Immuno-oncology Drugs, by Sales Channel USD Million (2018-2023)
  • Table 85. Italy Immuno-oncology Drugs, by Type USD Million (2018-2023)
  • Table 86. Italy Immuno-oncology Drugs, by Application USD Million (2018-2023)
  • Table 87. Italy Immuno-oncology Drugs, by Therapies USD Million (2018-2023)
  • Table 88. Italy Immuno-oncology Drugs, by Sales Channel USD Million (2018-2023)
  • Table 89. United Kingdom Immuno-oncology Drugs, by Type USD Million (2018-2023)
  • Table 90. United Kingdom Immuno-oncology Drugs, by Application USD Million (2018-2023)
  • Table 91. United Kingdom Immuno-oncology Drugs, by Therapies USD Million (2018-2023)
  • Table 92. United Kingdom Immuno-oncology Drugs, by Sales Channel USD Million (2018-2023)
  • Table 93. Netherlands Immuno-oncology Drugs, by Type USD Million (2018-2023)
  • Table 94. Netherlands Immuno-oncology Drugs, by Application USD Million (2018-2023)
  • Table 95. Netherlands Immuno-oncology Drugs, by Therapies USD Million (2018-2023)
  • Table 96. Netherlands Immuno-oncology Drugs, by Sales Channel USD Million (2018-2023)
  • Table 97. Rest of Europe Immuno-oncology Drugs, by Type USD Million (2018-2023)
  • Table 98. Rest of Europe Immuno-oncology Drugs, by Application USD Million (2018-2023)
  • Table 99. Rest of Europe Immuno-oncology Drugs, by Therapies USD Million (2018-2023)
  • Table 100. Rest of Europe Immuno-oncology Drugs, by Sales Channel USD Million (2018-2023)
  • Table 101. MEA Immuno-oncology Drugs, by Country USD Million (2018-2023)
  • Table 102. MEA Immuno-oncology Drugs, by Type USD Million (2018-2023)
  • Table 103. MEA Immuno-oncology Drugs, by Application USD Million (2018-2023)
  • Table 104. MEA Immuno-oncology Drugs, by Therapies USD Million (2018-2023)
  • Table 105. MEA Immuno-oncology Drugs, by Sales Channel USD Million (2018-2023)
  • Table 106. Middle East Immuno-oncology Drugs, by Type USD Million (2018-2023)
  • Table 107. Middle East Immuno-oncology Drugs, by Application USD Million (2018-2023)
  • Table 108. Middle East Immuno-oncology Drugs, by Therapies USD Million (2018-2023)
  • Table 109. Middle East Immuno-oncology Drugs, by Sales Channel USD Million (2018-2023)
  • Table 110. Africa Immuno-oncology Drugs, by Type USD Million (2018-2023)
  • Table 111. Africa Immuno-oncology Drugs, by Application USD Million (2018-2023)
  • Table 112. Africa Immuno-oncology Drugs, by Therapies USD Million (2018-2023)
  • Table 113. Africa Immuno-oncology Drugs, by Sales Channel USD Million (2018-2023)
  • Table 114. North America Immuno-oncology Drugs, by Country USD Million (2018-2023)
  • Table 115. North America Immuno-oncology Drugs, by Type USD Million (2018-2023)
  • Table 116. North America Immuno-oncology Drugs, by Application USD Million (2018-2023)
  • Table 117. North America Immuno-oncology Drugs, by Therapies USD Million (2018-2023)
  • Table 118. North America Immuno-oncology Drugs, by Sales Channel USD Million (2018-2023)
  • Table 119. United States Immuno-oncology Drugs, by Type USD Million (2018-2023)
  • Table 120. United States Immuno-oncology Drugs, by Application USD Million (2018-2023)
  • Table 121. United States Immuno-oncology Drugs, by Therapies USD Million (2018-2023)
  • Table 122. United States Immuno-oncology Drugs, by Sales Channel USD Million (2018-2023)
  • Table 123. Canada Immuno-oncology Drugs, by Type USD Million (2018-2023)
  • Table 124. Canada Immuno-oncology Drugs, by Application USD Million (2018-2023)
  • Table 125. Canada Immuno-oncology Drugs, by Therapies USD Million (2018-2023)
  • Table 126. Canada Immuno-oncology Drugs, by Sales Channel USD Million (2018-2023)
  • Table 127. Mexico Immuno-oncology Drugs, by Type USD Million (2018-2023)
  • Table 128. Mexico Immuno-oncology Drugs, by Application USD Million (2018-2023)
  • Table 129. Mexico Immuno-oncology Drugs, by Therapies USD Million (2018-2023)
  • Table 130. Mexico Immuno-oncology Drugs, by Sales Channel USD Million (2018-2023)
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Company Basic Information, Sales Area and Its Competitors
  • Table 146. Company Basic Information, Sales Area and Its Competitors
  • Table 147. Company Basic Information, Sales Area and Its Competitors
  • Table 148. Immuno-oncology Drugs: by Type(USD Million)
  • Table 149. Immuno-oncology Drugs Immune Checkpoint Inhibitors , by Region USD Million (2025-2030)
  • Table 150. Immuno-oncology Drugs Monoclonal Antibodies , by Region USD Million (2025-2030)
  • Table 151. Immuno-oncology Drugs Cytokine-Based Immunotherapy , by Region USD Million (2025-2030)
  • Table 152. Immuno-oncology Drugs Cancer Vaccines , by Region USD Million (2025-2030)
  • Table 153. Immuno-oncology Drugs CAR-T Cell Therapy , by Region USD Million (2025-2030)
  • Table 154. Immuno-oncology Drugs: by Application(USD Million)
  • Table 155. Immuno-oncology Drugs Hospitals , by Region USD Million (2025-2030)
  • Table 156. Immuno-oncology Drugs Pharmacies , by Region USD Million (2025-2030)
  • Table 157. Immuno-oncology Drugs Online Pharmacies , by Region USD Million (2025-2030)
  • Table 158. Immuno-oncology Drugs: by Therapies(USD Million)
  • Table 159. Immuno-oncology Drugs Iplimumab , by Region USD Million (2025-2030)
  • Table 160. Immuno-oncology Drugs Nivolumab , by Region USD Million (2025-2030)
  • Table 161. Immuno-oncology Drugs Rituximab , by Region USD Million (2025-2030)
  • Table 162. Immuno-oncology Drugs Blinatumomab , by Region USD Million (2025-2030)
  • Table 163. Immuno-oncology Drugs Aldesleukin , by Region USD Million (2025-2030)
  • Table 164. Immuno-oncology Drugs Recombinant human papillomavirus vaccine (Gardasil) , by Region USD Million (2025-2030)
  • Table 165. Immuno-oncology Drugs Tisagenlecleucel (Kymriah) , by Region USD Million (2025-2030)
  • Table 166. Immuno-oncology Drugs: by Sales Channel(USD Million)
  • Table 167. Immuno-oncology Drugs Direct , by Region USD Million (2025-2030)
  • Table 168. Immuno-oncology Drugs Indirect , by Region USD Million (2025-2030)
  • Table 169. South America Immuno-oncology Drugs, by Country USD Million (2025-2030)
  • Table 170. South America Immuno-oncology Drugs, by Type USD Million (2025-2030)
  • Table 171. South America Immuno-oncology Drugs, by Application USD Million (2025-2030)
  • Table 172. South America Immuno-oncology Drugs, by Therapies USD Million (2025-2030)
  • Table 173. South America Immuno-oncology Drugs, by Sales Channel USD Million (2025-2030)
  • Table 174. Brazil Immuno-oncology Drugs, by Type USD Million (2025-2030)
  • Table 175. Brazil Immuno-oncology Drugs, by Application USD Million (2025-2030)
  • Table 176. Brazil Immuno-oncology Drugs, by Therapies USD Million (2025-2030)
  • Table 177. Brazil Immuno-oncology Drugs, by Sales Channel USD Million (2025-2030)
  • Table 178. Argentina Immuno-oncology Drugs, by Type USD Million (2025-2030)
  • Table 179. Argentina Immuno-oncology Drugs, by Application USD Million (2025-2030)
  • Table 180. Argentina Immuno-oncology Drugs, by Therapies USD Million (2025-2030)
  • Table 181. Argentina Immuno-oncology Drugs, by Sales Channel USD Million (2025-2030)
  • Table 182. Rest of South America Immuno-oncology Drugs, by Type USD Million (2025-2030)
  • Table 183. Rest of South America Immuno-oncology Drugs, by Application USD Million (2025-2030)
  • Table 184. Rest of South America Immuno-oncology Drugs, by Therapies USD Million (2025-2030)
  • Table 185. Rest of South America Immuno-oncology Drugs, by Sales Channel USD Million (2025-2030)
  • Table 186. Asia Pacific Immuno-oncology Drugs, by Country USD Million (2025-2030)
  • Table 187. Asia Pacific Immuno-oncology Drugs, by Type USD Million (2025-2030)
  • Table 188. Asia Pacific Immuno-oncology Drugs, by Application USD Million (2025-2030)
  • Table 189. Asia Pacific Immuno-oncology Drugs, by Therapies USD Million (2025-2030)
  • Table 190. Asia Pacific Immuno-oncology Drugs, by Sales Channel USD Million (2025-2030)
  • Table 191. China Immuno-oncology Drugs, by Type USD Million (2025-2030)
  • Table 192. China Immuno-oncology Drugs, by Application USD Million (2025-2030)
  • Table 193. China Immuno-oncology Drugs, by Therapies USD Million (2025-2030)
  • Table 194. China Immuno-oncology Drugs, by Sales Channel USD Million (2025-2030)
  • Table 195. Japan Immuno-oncology Drugs, by Type USD Million (2025-2030)
  • Table 196. Japan Immuno-oncology Drugs, by Application USD Million (2025-2030)
  • Table 197. Japan Immuno-oncology Drugs, by Therapies USD Million (2025-2030)
  • Table 198. Japan Immuno-oncology Drugs, by Sales Channel USD Million (2025-2030)
  • Table 199. India Immuno-oncology Drugs, by Type USD Million (2025-2030)
  • Table 200. India Immuno-oncology Drugs, by Application USD Million (2025-2030)
  • Table 201. India Immuno-oncology Drugs, by Therapies USD Million (2025-2030)
  • Table 202. India Immuno-oncology Drugs, by Sales Channel USD Million (2025-2030)
  • Table 203. South Korea Immuno-oncology Drugs, by Type USD Million (2025-2030)
  • Table 204. South Korea Immuno-oncology Drugs, by Application USD Million (2025-2030)
  • Table 205. South Korea Immuno-oncology Drugs, by Therapies USD Million (2025-2030)
  • Table 206. South Korea Immuno-oncology Drugs, by Sales Channel USD Million (2025-2030)
  • Table 207. Taiwan Immuno-oncology Drugs, by Type USD Million (2025-2030)
  • Table 208. Taiwan Immuno-oncology Drugs, by Application USD Million (2025-2030)
  • Table 209. Taiwan Immuno-oncology Drugs, by Therapies USD Million (2025-2030)
  • Table 210. Taiwan Immuno-oncology Drugs, by Sales Channel USD Million (2025-2030)
  • Table 211. Australia Immuno-oncology Drugs, by Type USD Million (2025-2030)
  • Table 212. Australia Immuno-oncology Drugs, by Application USD Million (2025-2030)
  • Table 213. Australia Immuno-oncology Drugs, by Therapies USD Million (2025-2030)
  • Table 214. Australia Immuno-oncology Drugs, by Sales Channel USD Million (2025-2030)
  • Table 215. Rest of Asia-Pacific Immuno-oncology Drugs, by Type USD Million (2025-2030)
  • Table 216. Rest of Asia-Pacific Immuno-oncology Drugs, by Application USD Million (2025-2030)
  • Table 217. Rest of Asia-Pacific Immuno-oncology Drugs, by Therapies USD Million (2025-2030)
  • Table 218. Rest of Asia-Pacific Immuno-oncology Drugs, by Sales Channel USD Million (2025-2030)
  • Table 219. Europe Immuno-oncology Drugs, by Country USD Million (2025-2030)
  • Table 220. Europe Immuno-oncology Drugs, by Type USD Million (2025-2030)
  • Table 221. Europe Immuno-oncology Drugs, by Application USD Million (2025-2030)
  • Table 222. Europe Immuno-oncology Drugs, by Therapies USD Million (2025-2030)
  • Table 223. Europe Immuno-oncology Drugs, by Sales Channel USD Million (2025-2030)
  • Table 224. Germany Immuno-oncology Drugs, by Type USD Million (2025-2030)
  • Table 225. Germany Immuno-oncology Drugs, by Application USD Million (2025-2030)
  • Table 226. Germany Immuno-oncology Drugs, by Therapies USD Million (2025-2030)
  • Table 227. Germany Immuno-oncology Drugs, by Sales Channel USD Million (2025-2030)
  • Table 228. France Immuno-oncology Drugs, by Type USD Million (2025-2030)
  • Table 229. France Immuno-oncology Drugs, by Application USD Million (2025-2030)
  • Table 230. France Immuno-oncology Drugs, by Therapies USD Million (2025-2030)
  • Table 231. France Immuno-oncology Drugs, by Sales Channel USD Million (2025-2030)
  • Table 232. Italy Immuno-oncology Drugs, by Type USD Million (2025-2030)
  • Table 233. Italy Immuno-oncology Drugs, by Application USD Million (2025-2030)
  • Table 234. Italy Immuno-oncology Drugs, by Therapies USD Million (2025-2030)
  • Table 235. Italy Immuno-oncology Drugs, by Sales Channel USD Million (2025-2030)
  • Table 236. United Kingdom Immuno-oncology Drugs, by Type USD Million (2025-2030)
  • Table 237. United Kingdom Immuno-oncology Drugs, by Application USD Million (2025-2030)
  • Table 238. United Kingdom Immuno-oncology Drugs, by Therapies USD Million (2025-2030)
  • Table 239. United Kingdom Immuno-oncology Drugs, by Sales Channel USD Million (2025-2030)
  • Table 240. Netherlands Immuno-oncology Drugs, by Type USD Million (2025-2030)
  • Table 241. Netherlands Immuno-oncology Drugs, by Application USD Million (2025-2030)
  • Table 242. Netherlands Immuno-oncology Drugs, by Therapies USD Million (2025-2030)
  • Table 243. Netherlands Immuno-oncology Drugs, by Sales Channel USD Million (2025-2030)
  • Table 244. Rest of Europe Immuno-oncology Drugs, by Type USD Million (2025-2030)
  • Table 245. Rest of Europe Immuno-oncology Drugs, by Application USD Million (2025-2030)
  • Table 246. Rest of Europe Immuno-oncology Drugs, by Therapies USD Million (2025-2030)
  • Table 247. Rest of Europe Immuno-oncology Drugs, by Sales Channel USD Million (2025-2030)
  • Table 248. MEA Immuno-oncology Drugs, by Country USD Million (2025-2030)
  • Table 249. MEA Immuno-oncology Drugs, by Type USD Million (2025-2030)
  • Table 250. MEA Immuno-oncology Drugs, by Application USD Million (2025-2030)
  • Table 251. MEA Immuno-oncology Drugs, by Therapies USD Million (2025-2030)
  • Table 252. MEA Immuno-oncology Drugs, by Sales Channel USD Million (2025-2030)
  • Table 253. Middle East Immuno-oncology Drugs, by Type USD Million (2025-2030)
  • Table 254. Middle East Immuno-oncology Drugs, by Application USD Million (2025-2030)
  • Table 255. Middle East Immuno-oncology Drugs, by Therapies USD Million (2025-2030)
  • Table 256. Middle East Immuno-oncology Drugs, by Sales Channel USD Million (2025-2030)
  • Table 257. Africa Immuno-oncology Drugs, by Type USD Million (2025-2030)
  • Table 258. Africa Immuno-oncology Drugs, by Application USD Million (2025-2030)
  • Table 259. Africa Immuno-oncology Drugs, by Therapies USD Million (2025-2030)
  • Table 260. Africa Immuno-oncology Drugs, by Sales Channel USD Million (2025-2030)
  • Table 261. North America Immuno-oncology Drugs, by Country USD Million (2025-2030)
  • Table 262. North America Immuno-oncology Drugs, by Type USD Million (2025-2030)
  • Table 263. North America Immuno-oncology Drugs, by Application USD Million (2025-2030)
  • Table 264. North America Immuno-oncology Drugs, by Therapies USD Million (2025-2030)
  • Table 265. North America Immuno-oncology Drugs, by Sales Channel USD Million (2025-2030)
  • Table 266. United States Immuno-oncology Drugs, by Type USD Million (2025-2030)
  • Table 267. United States Immuno-oncology Drugs, by Application USD Million (2025-2030)
  • Table 268. United States Immuno-oncology Drugs, by Therapies USD Million (2025-2030)
  • Table 269. United States Immuno-oncology Drugs, by Sales Channel USD Million (2025-2030)
  • Table 270. Canada Immuno-oncology Drugs, by Type USD Million (2025-2030)
  • Table 271. Canada Immuno-oncology Drugs, by Application USD Million (2025-2030)
  • Table 272. Canada Immuno-oncology Drugs, by Therapies USD Million (2025-2030)
  • Table 273. Canada Immuno-oncology Drugs, by Sales Channel USD Million (2025-2030)
  • Table 274. Mexico Immuno-oncology Drugs, by Type USD Million (2025-2030)
  • Table 275. Mexico Immuno-oncology Drugs, by Application USD Million (2025-2030)
  • Table 276. Mexico Immuno-oncology Drugs, by Therapies USD Million (2025-2030)
  • Table 277. Mexico Immuno-oncology Drugs, by Sales Channel USD Million (2025-2030)
  • Table 278. Research Programs/Design for This Report
  • Table 279. Key Data Information from Secondary Sources
  • Table 280. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Immuno-oncology Drugs: by Type USD Million (2018-2023)
  • Figure 5. Global Immuno-oncology Drugs: by Application USD Million (2018-2023)
  • Figure 6. Global Immuno-oncology Drugs: by Therapies USD Million (2018-2023)
  • Figure 7. Global Immuno-oncology Drugs: by Sales Channel USD Million (2018-2023)
  • Figure 8. South America Immuno-oncology Drugs Share (%), by Country
  • Figure 9. Asia Pacific Immuno-oncology Drugs Share (%), by Country
  • Figure 10. Europe Immuno-oncology Drugs Share (%), by Country
  • Figure 11. MEA Immuno-oncology Drugs Share (%), by Country
  • Figure 12. North America Immuno-oncology Drugs Share (%), by Country
  • Figure 13. Global Immuno-oncology Drugs share by Players 2023 (%)
  • Figure 14. Global Immuno-oncology Drugs share by Players (Top 3) 2023(%)
  • Figure 15. Global Immuno-oncology Drugs share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Amgen, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 18. Amgen, Inc (United States) Revenue: by Geography 2023
  • Figure 19. AstraZeneca, Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. AstraZeneca, Plc (United Kingdom) Revenue: by Geography 2023
  • Figure 21. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 22. Bristol-Myers Squibb (United States) Revenue: by Geography 2023
  • Figure 23. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 24. Celgene Corporation (United States) Revenue: by Geography 2023
  • Figure 25. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 26. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 27. Merck & Co.(United States) Revenue, Net Income and Gross profit
  • Figure 28. Merck & Co.(United States) Revenue: by Geography 2023
  • Figure 29. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2023
  • Figure 31. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 32. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 33. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Novartis International AG (Switzerland) Revenue: by Geography 2023
  • Figure 35. AbbVie, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. AbbVie, Inc. (United States) Revenue: by Geography 2023
  • Figure 37. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 39. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 40. Sanofi S.A. (France) Revenue: by Geography 2023
  • Figure 41. EMD Serono, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. EMD Serono, Inc. (United States) Revenue: by Geography 2023
  • Figure 43. Gilead Sciences Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. Gilead Sciences Inc. (United States) Revenue: by Geography 2023
  • Figure 45. Prometheus Therapeutics & Diagnostics (United States) Revenue, Net Income and Gross profit
  • Figure 46. Prometheus Therapeutics & Diagnostics (United States) Revenue: by Geography 2023
  • Figure 47. Aduro BioTech (United States) Revenue, Net Income and Gross profit
  • Figure 48. Aduro BioTech (United States) Revenue: by Geography 2023
  • Figure 49. Galena Biopharma (United States) Revenue, Net Income and Gross profit
  • Figure 50. Galena Biopharma (United States) Revenue: by Geography 2023
  • Figure 51. Global Immuno-oncology Drugs: by Type USD Million (2025-2030)
  • Figure 52. Global Immuno-oncology Drugs: by Application USD Million (2025-2030)
  • Figure 53. Global Immuno-oncology Drugs: by Therapies USD Million (2025-2030)
  • Figure 54. Global Immuno-oncology Drugs: by Sales Channel USD Million (2025-2030)
  • Figure 55. South America Immuno-oncology Drugs Share (%), by Country
  • Figure 56. Asia Pacific Immuno-oncology Drugs Share (%), by Country
  • Figure 57. Europe Immuno-oncology Drugs Share (%), by Country
  • Figure 58. MEA Immuno-oncology Drugs Share (%), by Country
  • Figure 59. North America Immuno-oncology Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Amgen, Inc (United States)
  • AstraZeneca, Plc (United Kingdom)
  • Bristol-Myers Squibb (United States)
  • Celgene Corporation (United States)
  • Eli Lilly and Company (United States)
  • Merck & Co.(United States)
  • Hoffmann-La Roche AG (Switzerland)
  • Johnson & Johnson (United States)
  • Novartis International AG (Switzerland)
  • AbbVie, Inc. (United States)
  • Pfizer Inc. (United States)
  • Sanofi S.A. (France)
  • EMD Serono, Inc. (United States)
  • Gilead Sciences Inc. (United States)
  • Prometheus Therapeutics & Diagnostics (United States)
  • Aduro BioTech (United States)
  • Galena Biopharma (United States)
Additional players considered in the study are as follows:
Bavarian Nordic (Denmark) , Celldex Therapeutics (United States) , ImmunoCellular Therapeutics (United States) , Incyte Corporation (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 203 Pages 74 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Immuno-oncology Drugs Market Quantitative research analysis
Global Immuno-oncology Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2018-2023; Base year: 2023; Forecast period: 2024 to 2030
Companies that are profiled in Global Immuno-oncology Drugs Market are Amgen, Inc (United States), AstraZeneca, Plc (United Kingdom), Bristol-Myers Squibb (United States), Celgene Corporation (United States), Eli Lilly and Company (United States), Merck & Co.(United States), Hoffmann-La Roche AG (Switzerland), Johnson & Johnson (United States), Novartis International AG (Switzerland), AbbVie, Inc. (United States), Pfizer Inc. (United States), Sanofi S.A. (France), EMD Serono, Inc. (United States), Gilead Sciences Inc. (United States), Prometheus Therapeutics & Diagnostics (United States), Aduro BioTech (United States) and Galena Biopharma (United States) etc.
Hospitals segment in Global market to hold robust market share owing to "Introduction of Novel Oncology Therapies with Lesser Side Effects ".
AMA Research predicts that United States Players will contribute to the maximum growth of Global Immuno-oncology Drugs market throughout the forecasted period.

Know More About Global Immuno-oncology Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Testosterone Cypionate Comprehensive Study by Application (Primary Hypogonadism, Hypogonadotropic Hypogonadism, Late-Onset Hypogonadism), Route of Administration (Injectable, Parenteral), Active Ingr...
$ 3650
Central Lab Services Comprehensive Study by Type (Medical Microbiology & Cytology, Blood Bank/ Transfusion Medicine, HLA Typing, Toxicology, Andrology, Hematology, Clinical Chemistry, Endocrinology, ...
$ 3750
Ophthalmic Lenses Comprehensive Study by Type (Single-Vision Lens, Multifocal Lenses (Bifocal and Trifocal Lenses), Progressive Lenses, Light Protection Lenses (Tints, Blue Blocking Filters, Polarisi...
$ 3750
Embryonic Stem Cell Comprehensive Study by Application (Neurological Disorders, Orthopedic Treatments, Oncology Disorders, Diabetes, Injuries and Wounds, Cardiovascular Disorders, Others (Drug Develo...
$ 3450
Probiotic Comprehensive Study by Application (Food and Beverages, Dietary Supplements, Animal Feed), Strains (Animalis, Breve, Lactis (Buttermilk, Cottage cheese, other cheeses), Longum, Acidophilus,...
$ 3750
D-Ribose Comprehensive Study by Type (Food Grade D-Ribose, Pharmaceutical Grade D-Ribose), Application (Pharmaceutical Intermediate, Food Additives, Sports Supplement, Health Products), Form (Crystal...
$ 3650